Voya Investment Management LLC lowered its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 19.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 348,161 shares of the company’s stock after selling 83,533 shares during the period. Voya Investment Management LLC owned approximately 0.37% of Spyre Therapeutics worth $30,997,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in SYRE. Integrated Wealth Concepts LLC bought a new stake in shares of Spyre Therapeutics during the second quarter valued at about $31,000. GAMMA Investing LLC lifted its holdings in Spyre Therapeutics by 26.8% in the second quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $59,000 after purchasing an additional 140 shares during the period. IFP Advisors Inc grew its position in Spyre Therapeutics by 3,241.7% in the 3rd quarter. IFP Advisors Inc now owns 802 shares of the company’s stock valued at $71,000 after buying an additional 778 shares in the last quarter. SBI Securities Co. Ltd. grew its position in Spyre Therapeutics by 20,420.0% in the 3rd quarter. SBI Securities Co. Ltd. now owns 1,026 shares of the company’s stock valued at $91,000 after buying an additional 1,021 shares in the last quarter. Finally, KBC Group NV bought a new position in Spyre Therapeutics in the 1st quarter valued at about $69,000. Institutional investors and hedge funds own 80.39% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have commented on the stock. Wall Street Zen downgraded shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Robert W. Baird set a $120.00 price objective on shares of Spyre Therapeutics in a report on Wednesday, August 5th. UBS Group assumed coverage on shares of Spyre Therapeutics in a research note on Sunday, October 11th. They set a “buy” rating and a $120.00 price objective on the stock. Wolfe Research cut Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Tuesday, July 28th. Finally, Deutsche Bank cut their target price on Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday, August 26th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.53.
View Our Latest Report on Spyre Therapeutics
Spyre Therapeutics Trading Down 4.3%
Shares of NASDAQ SYRE opened at $93.47 on Friday. Spyre Therapeutics, Inc. has a twelve month low of $23.01 and a twelve month high of $110.64. The firm has a 50-day moving average of $92.28 and a two-hundred day moving average of $77.91. The company has a market capitalization of $8.88 billion, a price-to-earnings ratio of -34.11 and a beta of 3.24.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). As a group, research analysts predict that Spyre Therapeutics, Inc. will post -2.81 earnings per share for the current year.
Insiders Place Their Bets
In other Spyre Therapeutics news, CFO Scott Burrows sold 18,232 shares of Spyre Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $89.35, for a total value of $1,629,029.20. Following the transaction, the chief financial officer owned 79,762 shares in the company, valued at approximately $7,126,734.70. The trade was a 18.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Heidy King-Jones sold 28,933 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $91.03, for a total value of $2,633,770.99. Following the completion of the transaction, the insider directly owned 2,845 shares in the company, valued at $258,980.35. This represents a 91.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 138,064 shares of company stock worth $12,349,518. 15.69% of the stock is owned by insiders.
Spyre Therapeutics Profile
Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.
Further Reading
- Five stocks we like better than Spyre Therapeutics
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
